KRAS and non-small cell lung carcinoma: Evaluation of EGFR and KRAS mutations could predict the RR and PFS after erlotinib administration, and histologically enriched subsets derived from patients could help with clinical NSCLC trials of the use of EGFR-directed therapies [235].